Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 7/20 | 0.53 |
| ▸ | NPY4R | P50391 | 7/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.53 |
| ▸ | NPY1R | P25929 | 6/20 | 0.53 |
| ▸ | KDM1A | O60341 | 3/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.51 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710469 | 0.86 | EPHA2 (0.58) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| Oncocin SCHEMBL29538886 | 0.86 | KDM1A (0.62) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL30176214 | 0.85 | KDM1A (0.60) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL17980306 | 0.85 | OPRM1 (0.54) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL29973144 | 0.85 | NPY2R (0.57) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL31415954 | 0.85 | KDM1A (0.56) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL29855986 | 0.85 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RKDM1A | |
| SCHEMBL29477190 | 0.84 | TFPI (0.61) | KDM1ACXCL8NMUR2NMUR1 | |
| SCHEMBL30186432 | 0.84 | MC4R (0.63) | NPY2RNPY4RNPY5RNPY1RCXCL8 | |
| SCHEMBL29503865 | 0.84 | EPHA2 (0.58) | NPY1REPHA2CXCL8NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12098217-B2 | Fusion peptides as antimicrobial agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12098217-B2 | Fusion peptides as antimicrobial agents | ARG1, ARGLU1, PELP1 | NPY2R 859/4885NPY4R 823/4885NPY5R 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.